The benign prostatic hyperplasic devices market in North America is expected to grow from US$ 863.12 million in 2022 to US$ 1,349.19 million by 2028; it is estimated to grow at a CAGR of 7.7% from 2022 to 2028.
Benign prostatic hyperplasia (BPH) is a prostate enlargement caused by excessive cell growth in the prostate. This noncancerous prostate condition is usually not fatal. Being benign, the condition does not involve metastasis to other body parts. BPH is not associated with the risk of prostate cancer; moreover, unless it manifests symptoms, BPH isn’t considered a health issue. Almost all men are likely to have some prostate growth by the time they turn 70. Aging, abdominal obesity, and insufficient physical exercise raise the risk of developing BPH. According to the National Center for Biotechnology Information (NCBI), BPH is one of the most common disorders in older men and the leading cause of lower urinary tract symptoms (LUTS). After the age of 40, the prevalence of BPH rises, reaching a peak of 60% by the age of 90. Many autopsy studies suggest that the histological prevalence of BPH is 8%, 50%, and 80% in the fourth, sixth, and ninth decades of the life of a man, respectively. Old age has also been shown to be a risk factor for the onset and progression of clinical BPH in observational studies conducted in the US. According to statistics from the Krimpen and Baltimore Longitudinal Study of Aging, the prostate grows at a rate of 2.0–2.5% per year in elderly men. Continued prostate enlargement may develop into LUTS, and larger prostates are associated with a benign prostatic enlargement (BPE), which triggers the risk of developing clinical BPH and urine incontinence. According to the NCBI data, increased adiposity is found to have a positive correlation with prostate volume. In numerous study groups, body weight, body mass index (BMI), and waist circumference have been seen to have a positive correlation with prostate volume. Additionally, epidemiological data shows obesity may raise the need for BPH surgery and BPH treatment.
According to the American Journal of Men’s Health (AJMH), in 2019, globally, there were 11.26 million new cases and 1.86 million YLD due to BPH in 2019. The incidence of BPH increased by 105.7%, and YLD increased by 110.6% worldwide during 1990–2019. The absolute incidence and YLD numbers increased considerably worldwide during this period, primarily, due to population increase and aging. The treatment option for BPH includes surgeries such as transurethral resection of the prostate (TURP), open prostatectomy, and minimally invasive treatments such as transurethral needle ablation (TUNA). Benign prostatic hyperplasic devices are used in minimally invasive treatments such as radiofrequency ablation, laser therapy, and implants. Thus, the increase in the prevalence of benign prostatic hyperplasia and related risk factors bolsters the demand for benign prostatic hyperplasic devices.
North America Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)

North America Benign Prostatic Hyperplasic Devices Market Segmentation
The North America benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period. Based on procedure type, the North America benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period. Based on end user, the North America benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period. Based on country, the North America benign prostatic hyperplasic devices market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share, and it is further expected to register the highest CAGR during the forecast period.
KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; Richard Wolf GmbH; Urologix, LLC; OmniGuide Holdings, Inc.; and Convergent Laser Technologies are among the leading companies in the North America benign prostatic hyperplasic devices market.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Benign Prostatic Hyperplasic Devices Market – By Product
1.3.2 North America Benign Prostatic Hyperplasic Devices Market – By Procedure Type
1.3.3 North America Benign Prostatic Hyperplasic Devices Market – By End User
1.3.4 North America Benign Prostatic Hyperplasic Devices Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Benign Prostatic Hyperplasic Devices Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. North America Benign Prostatic Hyperplasic Devices Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Surging Prevalence of Benign Prostatic Hyperplasia along with Growing Risk Factors
5.1.2 Increasing Investments, Funds, and Grants for Research in BPH Treatment
5.2 Market Restraints
5.2.1 Limited Awareness of Prostate Health Among Men
5.3 Market Opportunities
5.3.1 Emerging Markets
5.4 Future Trends
5.4.1 Heighten Product Approvals and Launches
5.5 Impact Analysis
6. North America Benign Prostatic Hyperplasic Devices Market Analysis
6.1 North America Benign Prostatic Hyperplasic Devices Market Revenue Forecast and Analysis
7. North America Benign Prostatic Hyperplasic Devices Market – by Product
7.1 North America Benign Prostatic Hyperplasic Devices Market Revenue Share, by Product (2022 and 2028)
7.2 Resectoscopes
7.2.1 Overview
7.2.2 Resectoscopes: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.3 Urology Lasers
7.3.1 Overview
7.3.2 Urology Lasers: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Radiofrequency Ablation Devices
7.4.1 Overview
7.4.2 Radiofrequency Ablation Devices: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Prostatic Stents
7.5.1 Overview
7.5.2 Prostatic Stents: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Implants
7.6.1 Overview
7.6.2 Implants: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Benign Prostatic Hyperplasic Devices Market – by Procedure Type
8.1 North America Benign Prostatic Hyperplasic Devices Market Revenue Share, by Procedure Type (2022 and 2028)
8.2 Transurethral Microwave Therapy
8.2.1 Overview
8.2.2 Transurethral Microwave Therapy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Transurethral Resection of the Prostate
8.3.1 Overview
8.3.2 Transurethral Resection of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Transurethral Needle Ablation of the Prostate
8.4.1 Overview
8.4.2 Transurethral Needle Ablation of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Laser Surgery
8.5.1 Overview
8.5.2 Laser Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.6 UroLift Surgery
8.6.1 Overview
8.6.2 UroLift Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Benign Prostatic Hyperplasic Devices Market – by End User
9.1 Overview
9.2 North America Benign Prostatic Hyperplasic Devices Market Revenue Share, by End User (2022 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Ambulatory Surgical Centers
9.5.1 Overview
9.5.2 Ambulatory Surgical Centers Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)
10. North America Benign Prostatic Hyperplasic Devices Market – by Country Analysis
10.1 Overview
10.1.1 North America: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2 North America: Benign Prostatic Hyperplasic Devices Market, by Product, 2019–2028 (US$ Million)
10.1.3 North America: Benign Prostatic Hyperplasic Devices Market, by Procedure Type, 2019–2028 (US$ Million)
10.1.4 North America: Benign Prostatic Hyperplasic Devices Market, by End User, 2019–2028 (US$ Million)
10.1.5 North America: Benign Prostatic Hyperplasic Devices Market, by Country, 2022 & 2028 (%)
10.1.5.1 US: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.1.1 Overview
10.1.5.1.2 US: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.1.3 US: Benign Prostatic Hyperplasic Devices Market, by Product, 2019–2028 (US$ Million)
10.1.5.1.4 US: Benign Prostatic Hyperplasic Devices Market, by Procedure Type, 2019–2028 (US$ Million)
10.1.5.1.5 US: Benign Prostatic Hyperplasic Devices Market, by End User, 2019–2028 (US$ Million)
10.1.5.2 Canada: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.2.1 Overview
10.1.5.2.2 Canada: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.2.3 Canada: Benign Prostatic Hyperplasic Devices Market, by Product, 2019–2028 (US$ Million)
10.1.5.2.4 Canada: Benign Prostatic Hyperplasic Devices Market, by Procedure Type, 2019–2028 (US$ Million)
10.1.5.2.5 Canada: Benign Prostatic Hyperplasic Devices Market, by End User, 2019–2028 (US$ Million)
10.1.5.3 Mexico: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.3.1 Overview
10.1.5.3.2 Mexico: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.3.3 Mexico: Benign Prostatic Hyperplasic Devices Market, by Product, 2019–2028 (US$ Million)
10.1.5.3.4 Mexico: Benign Prostatic Hyperplasic Devices Market, by Procedure Type, 2019–2028 (US$ Million)
10.1.5.3.5 Mexico: Benign Prostatic Hyperplasic Devices Market, by End User, 2019–2028 (US$ Million)
11. North America Benign Prostatic Hyperplasic Devices Market – Industry Landscape
11.1 Overview
11.2 Inorganic Growth Strategies
11.3 Organic Growth Strategies
12. Company Profiles
12.1 KARL STORZ SE & Co. KG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Richard Wolf GmbH
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Olympus Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Urologix, LLC.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Boston Scientific Corporation
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Butterfly
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Teleflex Incorporated
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 OmniGuide Holdings, Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Convergent Laser Technologies
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 ProArc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms for Benign Prostatic Hyperplasia Devices Market

LIST OF TABLES
Table 1.             North America Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 2.             North America Benign Prostatic Hyperplasic Devices Market, by Procedure Type– Revenue and Forecast to 2028 (US$ Million)
Table 3.             North America Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 4.             US Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 5.             US Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 6.             US Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7.             Canada Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 8.             Canada Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 9.             Canada Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 10.          Mexico Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 11.          Mexico Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 12.          Mexico Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028  (US$ Million)
Table 13.          Recent Inorganic Growth Strategies in the Benign Prostatic Hyperplasia Devices Market
Table 14.          Recent Organic Growth Strategies in the Benign Prostatic Hyperplasia Devices Market
Table 15.          Glossary of Terms
 
 

LIST OF FIGURES
Figure 1.           North America Benign Prostatic Hyperplasic Devices Market Segmentation
Figure 2.           North America Benign Prostatic Hyperplasic Devices Market, By Country
Figure 3.           North America Benign Prostatic Hyperplasic Devices Market Overview
Figure 4.           Resectoscopes Segment Held Largest Share of Product Segment in Benign Prostatic Hyperplasic Devices Market
Figure 5.           The US is Expected to Show Remarkable Growth During the Forecast Period
Figure 6.           North America Benign Prostatic Hyperplasic Devices Market, Industry Landscape
Figure 7.           North America: PEST Analysis
Figure 8.           Experts Opinion
Figure 9.           North America Benign Prostatic Hyperplasic Devices Market – Revenue Forecast and Analysis – 2020-2028
Figure 10.        North America Benign Prostatic Hyperplasic Devices Market Revenue Share, by Product (2022 and 2028)
Figure 11.        Resectoscopes: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12.        Urology Lasers: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13.        Radiofrequency Ablation Devices: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14.        Prostatic Stents: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15.        Implants: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16.        North America Benign Prostatic Hyperplasic Devices Market Revenue Share, by Procedure Type (2022 and 2028)
Figure 17.        Transurethral Microwave Therapy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18.        Transurethral Resection of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19.        Transurethral Needle Ablation of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20.        Laser Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21.        UroLift Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22.        Others: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23.        North America Benign Prostatic Hyperplasic Devices Market Revenue Share, by End User (2022 and 2028)
Figure 24.        Hospitals Market Revenue and Forecast to 2028 (US$ Million)
Figure 25.        Clinics Market Revenue and Forecast to 2028 (US$ Million)
Figure 26.        Ambulatory Surgical Centers Market Revenue and Forecast to 2028 (US$ Million)
Figure 27.        Others Market Revenue and Forecast to 2028 (US$ Million)
Figure 28.        North America: Benign Prostatic Hyperplasic Devices Market, by Key Country – Revenue (2022) (US$ Million)
Figure 29.        North America Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
Figure 30.        North America: Benign Prostatic Hyperplasic Devices Market, by Country, 2022 & 2028 (%)
Figure 31.        US: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32.        Canada: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33.        Mexico: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America benign prostatic hyperplasic devices market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the North America benign prostatic hyperplasic devices market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the benign prostatic hyperplasic devices market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

The List of Companies – North America Benign Prostatic Hyperplasic Devices Market

● KARL STORZ SE & Co. KG
● Olympus Corporation
● Boston Scientific Corporation
● Teleflex Incorporated
● Richard Wolf GmbH                                 
● Urologix, LLC.                                            
● OmniGuide Holdings, Inc.                        
● Convergent Laser Technologies              

At 7.7% CAGR, the North America Benign Prostatic Hyperplasic Devices Market is speculated to be worth US$ 1,349.19 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the North America benign prostatic hyperplasic devices market was valued at US$ 863.12 million in 2022 and is expected to reach US$ 1,349.19 million by 2028, registering an annual growth rate of 7.7% from 2022 to 2028. Emerging markets and surging prevalence of BPH among men along with increasing.

Leading players in the benign prostatic hyperplasic devices market focus on expanding their customer reach across emerging markets by expanding their distribution networks and augmenting manufacturing capabilities. Most players are shifting their focus to emerging markets with the maturing of the US market. In addition, high investments in life science and healthcare research in emerging countries play a crucial role in the upgrading of the latest technologies in developing countries. In turn, this supports the inclination toward advanced benign prostatic hyperplasia treatments. Crucial benign prostatic hyperplasic device manufacturers in Mexico is expected to witness lucrative opportunities in the future owing to the large patient pool and high benign prostatic hyperplasia prevalence, increasing disposable income, improving healthcare infrastructure, and growing medical tourism in these countries.

On the contrary, limited awareness about prostate health among men.

Based on product, the North America benign prostatic hyperplasic devices market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment held 35.0% market share in 2022, amassing US$ 301.77 million. It is projected to garner US$ 466.84 million by 2028 to expand at 7.5% CAGR during 2022–2028.

Based on procedure type, the North America benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held 29.1% market share in 2022, amassing US$ 251.26 million. It is projected to garner US$ 406.05 million by 2028 to expand at 8.3% CAGR during 2022–2028.

Based on end user, the North America benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 41.2% market share in 2022, amassing US$ 355.67 million. It is projected to garner US$ 550.28 million by 2028 to expand at 7.5% CAGR during 2022–2028

Based on country, the North America benign prostatic hyperplasic devices market has been segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 78.5% market share in 2022. It was assessed at US$ 677.60 million in 2022 and is likely to hit US$ 1,067.34 million by 2028, exhibiting a CAGR of 7.9% during the forecast period.

Key players dominating the North America benign prostatic hyperplasic devices market are KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; Richard Wolf GmbH; Urologix, LLC; OmniGuide Holdings, Inc.; and Convergent Laser Technologies among others.

In September 2021, Teleflex Incorporated’s two new UroLift System products, the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System, were launched at the American Urological Association (AUA) 2021 Annual Meeting. In August 2018, OmniGuide Holdings received U.S. Food and Drug Administration clearance for the RevoLix HTL, a family of pulsed and continuous wave Thulium YAG lasers. The product is used on urology patients undergoing benign prostatic hyperplasia (BPH) and stone management procedures.